SecBot SecBot
PRESS-RELEASE ·Filed Jun 2, 2026

TRDA

Entrada Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor mid-2026 for Cohort 1 dystrophin data, which will be the first efficacy readout for ENTR-601-45. Positive dystrophin expression could drive significant upside for this single-asset-stage biotech; negative or ambiguous data would be highly bearish. Until then, no near-term catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.64
T+0 close · Jun 2, 2026 · via day close
Latest settled
+5.42%
T+60 · $7.00
Vs SPY
+4.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $6.64entry
  2. T+1 · 6mo ago −0.90%α −0.18% · $6.58
  3. T+5 · 5mo ago −4.07%α −1.10% · $6.37
  4. T+20 · 5mo ago +14.31%α +15.87% · $7.59
  5. T+60 · 3mo ago +5.42%α +4.30% · $7.00

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Entrada Therapeutics announced that an independent DMC recommended dose escalation to 10 mg/kg in Cohort 2 of the ELEVATE-45-201 Phase 1/2 study for ENTR-601-45 in Duchenne muscular dystrophy (exon 45). The company remains on track to report Cohort 1 safety, PK, and dystrophin data in mid-2026, with Cohort 2 and 3 data to follow. This is a routine clinical progress update with no new efficacy data released, making the near-term impact neutral.

Key Facts

  • DMC recommended initiation of Cohort 2 at 10 mg/kg (up from 5 mg/kg in Cohort 1) after reviewing safety and PK data from 8 participants.
  • Company on track to report Cohort 1 data (safety, early PK, dystrophin) in mid-2026.
  • ELEVATE-45-201 is a Phase 1/2 MAD study of ENTR-601-45 for DMD patients amenable to exon 45 skipping.
  • Dosing regimen is once every six weeks; planned doses across three cohorts range from 5 mg/kg to 15 mg/kg.
  • No financial data, revenue, or earnings were disclosed in the press release.

Financial Impact

No financial figures disclosed; pre-revenue clinical-stage biotech.

Risk Factors

  • Cohort 1 data (mid-2026) may show insufficient dystrophin expression or safety signals, leading to program termination.
  • DMD exon 45 space is competitive (Sarepta's Casimersen already approved); differentiation on efficacy or dosing frequency is unproven.
  • Pre-revenue company with limited cash runway, future dilution risk for ongoing trials.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304981

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026